Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 6/20 | 0.48 |
| ▸ | JAK1 | P23458 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TYK2 | P29597 | 4/20 | 0.46 |
| ▸ | JAK3 | P52333 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3572764 | 0.89 | KCNMA1 (0.48) | KCNMA1MEN1KMT2AUSP2MAPK1 | |
| SCHEMBL3579336 | 0.83 | MEN1 (0.45) | KCNMA1MEN1KMT2AUSP2MAPK1 | |
| Hydrochloric Acid SCHEMBL3585786 | 0.83 | MEN1 (0.44) | KCNMA1MEN1KMT2AUSP2MAPK1 | |
| SCHEMBL14780738 | 0.79 | NPC1 (0.52) | KCNMA1MEN1KMT2AUSP2MAPK1 | |
| SCHEMBL14511716 | 0.77 | KCNMA1 (0.48) | KCNMA1MEN1KMT2AUSP2MAPK1 | |
| SCHEMBL1644740 | 0.75 | KCNMA1 (0.60) | KCNMA1MEN1KMT2AUSP2MAPK1 | |
| SCHEMBL546611 | 0.73 | LMNA (0.50) | MEN1KMT2AUSP2MAPK1SMN1; SMN2 | |
| SCHEMBL1646133 | 0.72 | EGFR (0.45) | KCNMA1MEN1KMT2AUSP2MAPK1 | |
| SCHEMBL8305800 | 0.71 | LMNA (0.49) | KMT2AUSP2MAPK1NPC1POLB | |
| SCHEMBL12252768 | 0.70 | NPC1 (0.56) | KCNMA1MEN1KMT2ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | CDK1, CDK3, CDK13 | KCNMA1 1684/4885MEN1 1244/4885KMT2A 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.